Satellos Bioscience Inc.: Satellos Bioscience Announces Q3 2022 Financial Results and Operational Highlights

Toronto, Ontario--(Newsfile Corp. - November 23, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a drug discovery company developing therapeutics to regenerate muscle

Related Keywords

United States ,Sherbrooke ,Quebec ,Canada ,United Kingdom ,Toronto ,Ontario ,British ,Christina Cameron ,Ryan Mitchell ,Phil Lambert ,Michael Rudnicki ,Frank Gleeson ,World Muscle Society Congress ,Regulatory Services Provider ,Technology Officer ,Newsfile Corp ,Nw Micelle Therapeutics Inc ,Ampb Technologies Inc ,Satellos Bioscience Inc ,Vico Therapeutics ,Nw Pharmatech Ltd ,Venture Exchange ,Business Development ,Research Agreement ,Expansion Indication ,Congenital Muscular Dystrophy Type ,Sponsored Research Agreement ,Ampb Tech ,Product Sublicense Agreement ,Immune Pharma ,Chief Technology ,British Columbia ,Listing Expense ,Satellos ,Ioscience ,Nnounces ,022 ,Financial ,Results ,Perational ,Highlights ,